• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Supernus Pharmaceuticals Inc.

    1/21/26 1:21:12 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SUPN alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Supernus Pharmaceuticals Inc

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    868459108

    (CUSIP Number)


    12/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    868459108


    1Names of Reporting Persons

    Dimensional Fund Advisors LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    2,650,157.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    2,712,341.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,712,341.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.7 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Supernus Pharmaceuticals Inc
    (b)Address of issuer's principal executive offices:

    9715 Key West Avenue, Rockville, MD 20850
    Item 2. 
    (a)Name of person filing:

    Dimensional Fund Advisors LP
    (b)Address or principal business office or, if none, residence:

    6300 Bee Cave Road, Building One, Austin, TX 78746
    (c)Citizenship:

    Delaware Limited Partnership
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    868459108
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    2,712,341 ** see Note 1 ** ** Note 1 ** Dimensional Fund Advisors LP, an investment adviser registered under Section 203 of the Investment Advisors Act of 1940, furnishes investment advice to four investment companies registered under the Investment Company Act of 1940, and serves as investment manager or sub-adviser to certain other commingled funds, group trusts and separate accounts (such investment companies, trusts and accounts, collectively referred to as the "Funds"). In certain cases, subsidiaries of Dimensional Fund Advisors LP may act as an adviser or sub-adviser to certain Funds. In its role as investment advisor, sub-adviser and/or manager, Dimensional Fund Advisors LP or its subsidiaries (collectively, "Dimensional") may possess voting and/or investment power over the securities of the Issuer that are owned by the Funds, and may be deemed to be the beneficial owner of the shares of the Issuer held by the Funds. However, all securities reported in this schedule are owned by the Funds. Dimensional disclaims beneficial ownership of such securities. In addition, the filing of this Schedule 13G shall not be construed as an admission that the reporting person or any of its affiliates is the beneficial owner of any securities covered by this Schedule 13G for any other purposes than Section 13(d) of the Securities Exchange Act of 1934.
    (b)Percent of class:

    4.7  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    2,650,157** see Note 1 **

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    2,712,341** see Note 1 **

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The Funds described in Note 1 above have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the securities held in their respective accounts. To the knowledge of Dimensional, the interest of any one such Fund does not exceed 5% of the class of securities. Dimensional Fund Advisors LP disclaims beneficial ownership of all such securities.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Dimensional Fund Advisors LP
     
    Signature:Selwyn Notelovitz
    Name/Title:Global Chief Compliance Officer
    Date:01/21/2026
    Get the next $SUPN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SUPN

    DatePrice TargetRatingAnalyst
    10/9/2025$65.00Neutral → Overweight
    Piper Sandler
    7/30/2025$42.00Neutral → Overweight
    Cantor Fitzgerald
    2/19/2025$57.00 → $36.00Overweight → Neutral
    Cantor Fitzgerald
    1/6/2025$57.00Overweight
    Cantor Fitzgerald
    9/11/2024$41.00 → $36.00Overweight → Neutral
    Piper Sandler
    1/3/2023$44.00 → $45.00Buy
    Jefferies
    12/1/2021$40.00 → $44.00Buy
    Jefferies
    More analyst ratings

    $SUPN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, Chief Medical Officer Rubin Jonathan covered exercise/tax liability with 675 shares and was granted 1,250 shares, increasing direct ownership by 5% to 13,341 units (SEC Form 4)

    4 - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Issuer)

    2/26/26 4:17:42 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP, Chief Tech. Ops. Officer Mottola Frank covered exercise/tax liability with 977 shares and was granted 1,875 shares, increasing direct ownership by 5% to 18,106 units (SEC Form 4)

    4 - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Issuer)

    2/26/26 4:19:59 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sr. VP of IP, CSO Bhatt Padmanabh P. was granted 1,250 shares and covered exercise/tax liability with 650 shares, increasing direct ownership by 4% to 17,044 units (SEC Form 4)

    4 - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Issuer)

    2/26/26 4:18:23 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SUPN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Supernus Pharma upgraded by Piper Sandler with a new price target

    Piper Sandler upgraded Supernus Pharma from Neutral to Overweight and set a new price target of $65.00

    10/9/25 8:22:44 AM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Supernus Pharma upgraded by Cantor Fitzgerald with a new price target

    Cantor Fitzgerald upgraded Supernus Pharma from Neutral to Overweight and set a new price target of $42.00

    7/30/25 7:19:36 AM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Supernus Pharma downgraded by Cantor Fitzgerald with a new price target

    Cantor Fitzgerald downgraded Supernus Pharma from Overweight to Neutral and set a new price target of $36.00 from $57.00 previously

    2/19/25 7:05:55 AM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SUPN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Supernus Announces Record Fourth Quarter and Full Year 2025 Financial Results

    Record total revenues of $211.6 million and $719.0 million in the fourth quarter and full year 2025, a 21% and 9% increase compared to same periods last year. Combined revenues of the Company's four growth products increased to $161.3 million and $521.8 million in the fourth quarter and full year 2025, representing year-over-year growth of 45% and 40% respectively. The strong growth in both periods was driven by an increase in net sales of Qelbree® and GOCOVRI®, and the addition of sales from ZURZUVAE® and ONAPGO™. Cash, cash equivalents and current marketable securities were $308.7 million at December 31, 2025. New patient initiation for ONAPGO resumed in the first quarter of 2026. Full

    2/24/26 4:05:00 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Supernus Pharmaceuticals to Participate in March Investor Conferences

    ROCKVILLE, Md., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that management will participate in the following March investor conferences: TD Cowen 46th Annual Health Care ConferenceDate:Fireside chat:Place:Webcast Link:Monday, March 2, 20262:30 p.m. ETBoston Marriott Copley Place, Boston, Mass.HereJefferies Biotech on the Beach SummitDate:Place:Tuesday, March 10, 20261 Hotel South Beach, Miami Beach, Fla.Barclays 28th Annual Global Healthcare ConferenceDate: Fireside chat: Place: Webcast Link:Wednesday

    2/23/26 6:15:00 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A

    AUSTIN, Texas, Feb. 17, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Biotech dealmaking is increasingly defined by a clear strategic shift: Pharmaceutical companies are prioritizing de-risked, late-stage assets with human clinical validation rather than speculative early-stage programs. After years of capital flowing into preclinical platforms with uncertain timelines, investors and acquirers are gravitating toward programs with established safety and efficacy data that can accelerate commercialization pathways. This evolving landscape naturally places companies such as Oncotelic Therapeutics Inc. (OTCQB:OTLC) (profile), which holds multiple clinical-stage and late-stage program

    2/17/26 8:30:00 AM ET
    $ARWR
    $JNJ
    $MGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $SUPN
    SEC Filings

    View All

    Supernus Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Filer)

    2/24/26 4:22:52 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Supernus Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Filer)

    2/24/26 4:13:59 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Supernus Pharmaceuticals Inc.

    SCHEDULE 13G/A - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Subject)

    2/18/26 4:38:59 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SUPN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Supernus Pharmaceuticals Inc.

    SC 13G/A - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Subject)

    11/14/24 5:14:42 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Supernus Pharmaceuticals Inc.

    SC 13G/A - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Subject)

    11/1/24 4:35:56 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Supernus Pharmaceuticals Inc.

    SC 13G - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Subject)

    10/31/24 11:55:00 AM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SUPN
    Financials

    Live finance-specific insights

    View All

    Supernus Announces Record Fourth Quarter and Full Year 2025 Financial Results

    Record total revenues of $211.6 million and $719.0 million in the fourth quarter and full year 2025, a 21% and 9% increase compared to same periods last year. Combined revenues of the Company's four growth products increased to $161.3 million and $521.8 million in the fourth quarter and full year 2025, representing year-over-year growth of 45% and 40% respectively. The strong growth in both periods was driven by an increase in net sales of Qelbree® and GOCOVRI®, and the addition of sales from ZURZUVAE® and ONAPGO™. Cash, cash equivalents and current marketable securities were $308.7 million at December 31, 2025. New patient initiation for ONAPGO resumed in the first quarter of 2026. Full

    2/24/26 4:05:00 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A

    AUSTIN, Texas, Feb. 17, 2026 (GLOBE NEWSWIRE) -- BioMedWire Editorial Coverage: Biotech dealmaking is increasingly defined by a clear strategic shift: Pharmaceutical companies are prioritizing de-risked, late-stage assets with human clinical validation rather than speculative early-stage programs. After years of capital flowing into preclinical platforms with uncertain timelines, investors and acquirers are gravitating toward programs with established safety and efficacy data that can accelerate commercialization pathways. This evolving landscape naturally places companies such as Oncotelic Therapeutics Inc. (OTCQB:OTLC) (profile), which holds multiple clinical-stage and late-stage program

    2/17/26 8:30:00 AM ET
    $ARWR
    $JNJ
    $MGTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 24, 2026

    ROCKVILLE, Md., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report fourth quarter and full year 2025 financial and business results after the market closes on Tuesday, February 24, 2026. Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a conference call to present the fourth quarter and full year 2025 financial and business results on Tuesday, February 24, 2026, at 4:30 p.m. ET. Following management's prepared remarks and discussion of

    2/12/26 4:35:00 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SUPN
    Leadership Updates

    Live Leadership Updates

    View All

    Jay Glazer Teams Up with Supernus Pharmaceuticals to Raise Awareness of ADHD and his Qelbree® Journey

    Jay is sharing his story of receiving an ADHD diagnosis and eventually finding his treatment approach with Qelbree15.7 million U.S. children, teens and adults estimated to have been diagnosed with ADHD1,2 ROCKVILLE, Md., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Television personality and sports reporter Jay Glazer is opening up about his personal experiences with attention-deficit/hyperactivity disorder (ADHD) – one of the most common psychiatric diagnoses affecting approximately 10 million adults in the U.S. – and with Qelbree (viloxazine extended-release capsules), a nonstimulant medication for the treatment of ADHD.3 Glazer, who has always been outspoken about his mental health struggles, wa

    10/16/23 5:34:21 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care